U.S. Markets open in 5 hrs 22 mins

Cassava Sciences, Inc. (SAVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9200-0.1300 (-4.26%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0500
Open3.0500
Bid0.0000 x 1200
Ask0.0000 x 1200
Day's Range2.9100 - 3.0700
52 Week Range1.0300 - 10.9500
Volume559,848
Avg. Volume4,238,992
Market Cap72.357M
Beta (5Y Monthly)2.92
PE Ratio (TTM)N/A
EPS (TTM)-0.2300
Earnings DateOct 27, 2020 - Nov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 13, 2012
1y Target Est16.00
  • Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%
    Zacks

    Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%

    Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • GlobeNewswire

    Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

    AUSTIN, Texas, July 09, 2020 -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist,.

  • GlobeNewswire

    Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update

    Cassava Sciences, Inc. (SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000® and Russell 3000® Indexes, effective after the close of the U.S. markets on Friday, June 26, 2020. “We are pleased Cassava Sciences is being added to these stock market indexes and are looking forward to building further awareness with the investor community about our focus on Alzheimer’s disease,” said Remi Barbier, President & CEO. “In addition, we look forward to announcing comprehensive study results from our Phase 2b study in approximately Q3 this year.”